Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ: HALO) beat Wall Street’s revenue expectations in Q3 2026, with sales up 39.2% year on year to $493 million. The company’s full-year revenue guidance of $1.89 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $2.39 per share was 1.5% above analysts’ consensus estimates.
Is now the time to buy HALO? Find out in our full research report (it’s free for active Edge members).
Halozyme Therapeutics (HALO) Q3 2026 highlights:
- Revenue $493 million vs S&P analysts’ estimates of $486.4 million (39.2% year-on-year growth, 1.3% beat)
- Adjusted EPS $2.39 vs S&P analysts’ estimates of $2.36 (1.5% beat)
- Adjusted EBITDA $336.2 million vs analyst estimates of $325.8 million (68.2% margin, 3.2% beat)
- Revenue guidance The company lifted its revenue guidance for the full year to $1.89 billion at the midpoint from $1.87 billion, a 1.1% increase
- Adjusted EPS guidance Management slightly raised its full-year adjusted EPS guidance to $8.90 at the midpoint
- EBITDA guidance $1.27 billion at the midpoint for the full year, above analyst estimates of $1.23 billion
- Operating margin 59.8%, down from 61.5% in the same quarter last year
- Market capitalization $13.96 billion
StockStory’s take
Halozyme Therapeutics delivered a quarter that surpassed Wall Street’s expectations, with revenue and non-GAAP profit both coming in above analyst forecasts. Despite this, the market responded negatively following the results. Management attributed the quarter’s strong growth to expanding royalty streams, particularly from the successful uptake of subcutaneous therapies enabled by ENHANZE. CEO Helen Torley highlighted the impact of new partner programs, accelerated adoption of products such as Ocrevus Zunovo and OPDIVO Qvantig, and continued growth from established products like DARZALEX and VYVGART Hytrulo as central drivers of performance.
Looking ahead, Halozyme’s updated guidance is underpinned by continued momentum in its royalty portfolio, new collaboration agreements, and advancing technologies such as Hypercon and Aerocon. Management emphasized that the next phase of growth will depend on successful clinical development, further partner product launches, and scaling new delivery platforms. CFO Darren Snellgrove pointed to ongoing investment in R&D and disciplined capital deployment as necessary to support both organic and partnership-driven opportunities, while noting that legal outcomes and execution on new technologies could influence the company’s long-term trajectory.
Key insights from management’s remarks
Management pointed to a robust pipeline and the expanding adoption of ENHANZE-enabled products as the central themes behind the latest quarter’s performance and improved guidance.
- Diversified royalty growth: Halozyme’s royalty revenue was fueled by both established and newer launches, with accelerated conversion to subcutaneous formulations in multiple therapeutic areas. Management cited strong uptake of Ocrevus Zunovo (Roche), OPDIVO Qvantig (Bristol Myers Squibb), and RYBREVANT FASPRO (Johnson & Johnson) among the highlights.
- Partner portfolio expansion: The company signed expanded agreements with three existing ENHANZE partners, adding four new target nominations. These additions are expected to further diversify and strengthen the royalty revenue pipeline, with CEO Helen Torley noting their potential to generate long-term value.
- Progress in next-generation platforms: Halozyme advanced its Hypercon and Aerocon technologies, which are designed to enable higher-concentration subcutaneous drug formulations. Management reported that Hypercon is on track for its first clinical trial starts in early 2027, and that several partners are actively progressing feasibility studies.
- Intellectual property defense: Legal victories in Europe protected Halozyme’s ENHANZE-related patents, blocking Merck’s KEYTRUDA subcutaneous product in key markets. Management emphasized these wins as reinforcing the company’s position as a leader in large-volume subcutaneous delivery.
- Operating leverage and capital allocation: CFO Darren Snellgrove highlighted ongoing investment in R&D and disciplined use of capital, including significant share repurchases and a recently completed $1.5 billion convertible note offering to bolster the balance sheet and fund growth initiatives.
Drivers of future performance
Halozyme’s near-term and long-term outlook will be shaped by the pace of partner product launches, expansion of next-generation platforms, and the durability of its royalty streams.
- Pipeline of new partner products: Management expects the addition of up to 13 new ENHANZE-enabled programs entering clinical development by year-end to contribute to future royalty revenue beginning in the late 2020s, assuming successful clinical progression and regulatory approvals.
- Commercialization of Hypercon and Aerocon: The company is targeting initial Hypercon clinical trials in early 2027, with subsequent milestones tied to partner adoption and proof-of-concept data. Management believes these platforms could significantly expand the company’s addressable market and royalty potential, but clinical and technical risks remain.
- Legal and competitive risks: Recent European patent victories have shielded key revenue streams, but ongoing U.S. litigation and potential royalty step-downs for certain products present uncertainties. Management acknowledged that successful defense and extension of intellectual property, along with timely partner launches, are critical for sustaining long-term growth.
Catalysts in upcoming quarters
In future quarters, our analysts will be watching (1) the pace of clinical advancement and partner launches for ENHANZE, Hypercon, and Aerocon programs, (2) the sustainability and growth in royalty revenue from both established and recently launched products, and (3) the resolution and impact of ongoing intellectual property litigation, particularly in the U.S. Execution on clinical milestones and successful partner adoption of next-generation platforms will be key indicators of Halozyme’s ability to deliver on its long-term growth strategy.
Halozyme Therapeutics currently trades at $114.26, down from $123.61 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).
Stocks that trumped tariffs
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
